About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

HKTDC releases research report on biomedicine, Industry development drives GBA global tech leadership



HONG KONG, Sep 15, 2025 - (ACN Newswire) – Hong Kong’s healthcare sector surged by nearly 30% in the last decade, with the total number of related businesses now exceeding 3,000. Details of this rapid and sustained growth are among the findings of a new study by HKTDC Research, titled “I&T Cooperation in the Guangdong-Hong Kong-Macao Greater Bay Area: Hong Kong Partners with Mainland Cities in Advancing Biomedical Upgrade in the GBA”.

This report was produced alongside “Seizing GBA Opportunities: Biomedical Co-operation and Development”, a joint research initiative with the Department of Commerce of Guangdong Province.

Overall, the research demonstrates that not only is Hong Kong successfully collaborating with key Guangdong GBA cities and Macao in biomedical innovation, but also that this collective endeavour is on course for sustained growth.

The successes to date have also been reflected primarily in the overall increase in the sector's value in regional terms.

Hong Kong in step with GBA biomedical partners

Just as Hong Kong has developed a sizable pharmaceutical and medical device cluster over recent years – with 3,020 related companies in 2023 as opposed to 2,340 in 2013 – so, too, has Guangdong looked to develop related resources.

Acknowledging the benefits of such a partnership, HKTDC Research Director Irina Fan said: “Thanks to extensive government support, technological innovation has been a key driver of Hong Kong’s economic growth, allowing it to effectively align with the national prioritisation of new quality productive forces. Earlier this year, the Guangdong Government announced action plans to grow its biomedical and healthcare industry cluster by around 50% by 2027, increasing its value from RMB 664 billion in 2023 to more than a trillion. Tellingly, a key element of this plan is to boost development by leveraging the existing strengths of the Hong Kong platform.”

“Being able to share this expertise with our partner cities in the GBA, with a particular focus on biomedicals, is a huge opportunity for all concerned and one set to deliver immense benefits nationally and even globally.”

Hong Kong: Driving biotech innovation

Among the many advantages global biotech businesses might seek to leverage is the comprehensive array of funding opportunities Hong Kong has access to, thanks to its status as a leading international financial centre.

As of June 2025, total market capitalisation of the Hong Kong-listed healthcare sector was US$441 billion – accounting for ~8.1% of the total market cap of Hong Kong-listed companies – which is three times the US$144 billion figure recorded at the end of 2017, pre-dating the launch of the HKEX Chapter 18A regime.

Since the Chapter 18A listing rules came into effect – which allows biotech firms without recorded revenue or profits to list – 73 biotech companies have listed, collectively raising US$16 billion as of mid-2025.

Expanding on the range of benefits Hong Kong can offer to biotech businesses based in partner GBA cities, Wing Chu, HKTDC Deputy Director of Research (Officer-in-Charge), said: “Beyond its financial resources, Hong Kong has several technical capabilities that will make a real difference to GBA businesses, as they look to expand their activities throughout the mainland and into many of the overseas markets. In particular, the city’s advanced clinical trial services, all of which yield internationally accepted data, make Hong Kong the ideal launchpad for any regional healthcare venture looking to go global.”

At present, the clinical data derived through Hong Kong-based trials has been approved for use by many of the world’s leading regulatory bodies, including the US Food and Drug Administration, the EU’s European Medicines Agency and Mainland China’s National Medical Products Administration (NMPA).

In addition, many of Hong Kong’s foremost healthcare institutions, including Queen Mary Hospital, Prince of Wales Hospital, Hong Kong Eye Hospital and Hong Kong Sanatorium & Hospital, have secured NMPA accreditation.

The GBA: A world-leading biotech innovation hub

In terms of international recognition, the World Intellectual Property Organization designated the Shenzhen-Hong Kong-Guangzhou cluster as the world’s leading innovation hub in its 2025 Global Innovation Index. This, in part at least, was in recognition of the lead role biotechnology plays within this cutting-edge cluster.

It is also important to acknowledge the extraordinary growth of Hong Kong’s biotech and health start-up sectors, which have developed far more rapidly than many comparable sectors.

Indeed, between 2018 and 2024, the number of Hong Kong-based biotech and healthtech start-ups more than quadrupled from 110 to 510, while the sectors’ share of the city’s total start-up ecosystem rose from 4% to 11%. This included a range of pioneering businesses in sectors, such as drug development, gene editing technology, medical device innovation and precision medical solutions.

Outlining how future intra-regional cooperation could benefit all parties, Cherry Yeung, HKTDC Research Senior Economist with oversight of these new reports, said: “Hong Kong is already seamlessly connected with many of the pharmaceutical manufacturers and markets in Mainland China, thanks to its strengths in R&D and international trade. For their part, the GBA cities deliver considerable production as well as resource support, creating a real synergy across the board. With Guangdong committed to further expanding its biomedical sector, this will foster a new generation of cross-industry collaboration.”

Photo download: http://bit.ly/4nc0SAc

Production and Trading of Drugs and Medical Supplies (Source: Census and Statistics Department of Hong Kong)

Between 2018 and 2024, the number of Hong Kong-based biotech and healthtech start-ups more than quadrupled from 110 to 510, while the sectors’ share of the city’s total start-up ecosystem rose from 4% to 11% (Source: InvestHK)


Media enquiries

Please contact the HKTDC’s Communication and Public Affairs Department:

Johnny Tsui

Tel: (852) 2584 4395

Email: johnny.cy.tsui@hktdc.org

About HKTDC

The Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitionsconferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus

]]>

Source: HKTDC

Copyright 2025 ACN Newswire . All rights reserved.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.